Viridian Therapeutics, Inc.\DE (VRDN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Viridian Therapeutics, Inc.\DE’s revenue went from $3M in fiscal 2016 to $71M in fiscal 2025, growth of about 39.8% a year.
Net income in fiscal 2025 was -$343M, a net margin of -483.6%; the best year in this period was 2016 with -$17M.
Over the twelve months to September 30, 2026, revenue was $26M and net income -$454M.
Free cash flow was -$277M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 277315% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26M | $71M | $302000 | $314000 | $2M | $3M | $1M | $4M | $8M | $4M | $3M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | $929000 |
| Operating income | -$469M | -$363M | -$299M | -$254M | -$134M | -$80M | -$110M | -$42M | -$33M | -$27M | -$17M |
| Net income | -$454M | -$343M | -$270M | -$238M | -$130M | -$79M | -$111M | -$42M | -$33M | -$27M | -$17M |
| EPS (diluted) | $-4.38 | $-3.02 | — | $-5.31 | $-4.05 | $-6.66 | $-31.13 | $-20.04 | $-16.50 | $-20.70 | $-423.15 |
| R&D | $309M | $339M | $238M | $160M | $101M | $57M | $28M | $35M | $30M | $20M | $14M |
| Revenue growth | — | +23359.9% | −3.8% | −82.3% | −40.2% | +182.2% | −76.5% | −46.8% | +109.5% | +15.1% | −39.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$342M | -$276M | -$232M | -$184M | -$94M | -$55M | -$30M | -$36M | -$27M | -$28M | -$15M |
| Capital spending | -$2M | -$495000 | -$511000 | -$898000 | -$797000 | -$338000 | -$42000 | -$84000 | -$445000 | -$246000 | -$250000 |
| Free cash flow | -$343M | -$277M | -$233M | -$185M | -$95M | -$55M | -$30M | -$36M | -$27M | -$28M | -$15M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | $2000 |
| Stock-based pay | $60M | $44M | $42M | $67M | $20M | $14M | $4M | $4M | $4M | $2M | $198000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $875M | $718M | $477M | $425M | $197M | $128M | $27M | $62M | $47M | $22M |
| Debt | — | $53M | $23M | $22M | $6M | $2M | $455000 | $9M | $10M | $10M | $5M |
| Equity | — | $722M | $672M | $442M | $395M | $188M | $120M | $16M | $51M | $39M | -$62M |
| Total assets | — | $899M | $742M | $490M | $435M | $204M | $131M | $30M | $66M | $52M | $25M |
| Shares (diluted) | 105M | 114M | — | 45M | 32M | 12M | 4M | 2M | 2M | 1M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | 26.7% |
| Operating margin | -1781.4% | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% | -10512.4% | -941.0% | -394.5% | -662.8% | -488.6% |
| Net margin | -1724.1% | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -496.8% |
| FCF margin | -1305.4% | -390.8% | -77096.0% | -58938.9% | -5340.6% | -1853.5% | -2840.1% | -810.1% | -325.4% | -709.8% | -431.6% |
| ROIC | — | -37.0% | -34.0% | -43.3% | -26.4% | -33.2% | -72.4% | -135.6% | -42.4% | -43.2% | — |
| ROE | — | -47.4% | -40.2% | -53.8% | -32.9% | -42.3% | -92.2% | -265.8% | -63.7% | -68.8% | 27.9% |
Frequently asked questions
What is Viridian Therapeutics, Inc.\DE’s annual revenue?
$71M in fiscal 2025 and $26M over the twelve months to September 30, 2026.
How much profit does Viridian Therapeutics, Inc.\DE make?
Net income was -$343M in fiscal 2025 (net margin -483.6%).
Is Viridian Therapeutics, Inc.\DE’s revenue growing?
Yes: revenue rose 23359.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.